This website is an international information resource intended for international healthcare professionals outside the United States of America (US) and the United Kingdom (UK) who are interested in information about Boehringer Ingelheim oncology.
While the Internet serves a global community, the pharmaceutical industry is subject to country-specific regulatory considerations. This means that compound status or the registration status and approved product labels of the products described within this website may not be the same in different countries.
Information about approved products on this website is derived from the Summary of Product Characteristics (SPC) for each product in the EU. It is not country-specific and may vary from the approved label in the country where you are located. Please refer to your local Prescribing Information for full details.
By clicking on the link below you are declaring and confirming that you are a healthcare professional outside the United States of America and the United Kingdom and have read and understood this disclaimer.
BI understand that continuing clinical research is needed to give better patient outcomes. Please see below to discover more about TKI sequencing and the video we have developed to illustrate the ever evolving landscape for treatment of EGFRM+ NSCLC.
Activating mutations in the epidermal growth factor receptor (EGFR) are known to be a driver of non-small cell lung carcinoma (NSCLC), and tyrosine kinase inhibitors (TKIs) that target these mutations are currently standard of care for first-line therapy in patients with EGFR mutation positive (EGFRM+) NSCLC. However, many patients with EGFRM+ disease eventually develop acquired resistance to these therapies, which most commonly occurs via T790M mutation.1 The clinical development of 3rd generation TKIs provides additional treatment options for these patients and can extend the chemotherapy-free interval. For clinicians seeking to further improve patient outcomes, this progress in clinical development raises questions about the optimal sequence of EGFR TKI therapies.
Two recent reviews discuss the sequential use of available EGFR TKIs and key considerations when assessing the optimal sequential therapy.2,3 In his review in Future Oncology, Prof. Nicolas Girard considers how selection of the optimal first-line treatment depends on patient factors such as the presence/absence of brain metastases, resistance mechanisms, subsequent therapy options for long-term treatment and the tolerability profile of the overall treatment sequence.2 Read the Girard review here and the Hirsh review here. Additional data are also required to further inform this important clinical topic.
Prof. Nicolas Girard discusses treatment sequencing with EGFR TKIs in EGFRM+ NSCLC
TKI sequencing in EGFRM+ NSCLC and insights from afatinib studies
Afatinib* is an irreversible ErbB Family blocker that selectively, potently and irreversibly binds to and blocks EGFR4,5. The video below shows how the landscape for treatment for EGFRM+ NSCLC has evolved, and how insights from afatinib* studies can inform treatment sequencing for patients with EGFRM+ NSCLC.
Sequencing: The bigger picture
To find out more about available clinical data on afatinib and treatment sequencing, please visit the afatinib clinical trial data and the NSCLC additional analyses and further trials pages. Additionally, GioTag, a real-world study of treatment sequencing in EGFRM+ NSCLC has recently been initiated.6
Novello S, et al. Ann Oncol 2016;27(suppl 5):v1–27.
Girard N. Future Oncol 2018; doi: 10.2217/fon-2017-0636 [Epub ahead of print].
Hirsh V. Ther Adv Med Oncol 2018; doi: 10.1177/1758834017753338 [Epub ahead of print].
Reid A, et al. Eur J Cancer 2007;43(3):481-9.
Li D, et al. Oncogene 2008;27(34):4702-11.
Boehringer Ingelheim. Press release. Available at: https://www.boehringer-ingelheim.com/press-release/giotagstudy (Accessed: December 2017).
*Afatinib is approved in more than 70 markets including the EU, Japan, Taiwan, and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list please see here. Registration conditions differ internationally; please refer to locally approved prescribing information.
© 2017 Boehringer Ingelheim International GmbH. All rights reserved.
Last updated: March 2018
Using this link will let you leave a website of Boehringer Ingelheim International GmbH (“BI”) or to a different domain under the control of BI. In the event that the linked site is not under the control of BI but under the control of a third party or an affiliate in the Boehringer Ingelheim group of companies, BI shall not be responsible for the contents, processing of personal data of any linked site or any link contained in a linked site, or any changes or updates to such sites. This link is provided to you only as a convenience, and the inclusion of any link does not imply endorsement by BI of the site.
Do you want to continue ?Continue